Aspen says it has capacity to help make monkeypox vaccine
The global pharmaceutical company revealed that it has the capacity to bottle monkeypox vaccines at its Gqeberha plant
Africa’s biggest pharmaceutical manufacturer Aspen Pharmacare says it is well-positioned to help produce monkeypox vaccines, as it has spare capacity at its sterile facility in Gqeberha.
The World Health Organisation (WHO) declared monkeypox a public health emergency of international concern on Saturday, as the viral disease has rapidly spread in the past few months. By Thursday, more than 18,000 cases had been detected in 75 countries. The disease is usually mild, but health authorities are anxious to contain its spread to reduce the risk of it mutating into a more severe form, and several governments, including the US and UK, snapping up limited vaccine supplies...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.